{
    "clinical_study": {
        "@rank": "95650", 
        "arm_group": {
            "arm_group_label": "FOLFOX6/Aflibercept/Radiation Therapy", 
            "arm_group_type": "Experimental", 
            "description": "Preoperative Chemoradiation:\n5-FU: 225 mg/m2 per day by intravenous continuous infusion (IVCI), Days 1 thru 42;\nRadiation: 50.4 Gy (1.8 Gy/day or 28 fractions) Mon thru Fri, Weeks 1 thru 6;\nAflibercept: 4 mg/ kg, via IV infusion, Days 1 and 15.\nSurgery:  Patients will undergo abdominoperineal or low anterior resection with total mesorectal excision, per standard treatment guidelines.\nPostoperative Chemotherapy and Aflibercept Treatments:\nAflibercept (administered first): 4 mg/kg IV for approximately 1 hour (no more than 2 hours) on Days 1 and 15 of each cycle.\nModified FOLFOX6:\nLeucovorin: 400 mg/m2 as a 2-hour infusion prior to 5-FU on Days 1 and 15 of  each cycle.\nOxaliplatin: 85 mg/m2 IV as a 2-hour infusion prior to 5-FU on Days 1 and 15 of each cycle.\n5-FU: 400-mg/m2 bolus for 2 to 4 minutes followed by 2400 mg/m2 for 46 hours on Days 1 and 15 of each cycle."
        }, 
        "brief_summary": {
            "textblock": "The purpose of this Phase II study will be to investigate the antiangiogenic agent,\n      aflibercept, in combination with chemoradiation as preoperative treatment for patients with\n      stage II/III rectal cancer, followed by 4 months of FOLFOX6 plus aflibercept adjuvantly."
        }, 
        "brief_title": "5-FU, Aflibercept, and Radiation (RT) for Preoperative and Postoperative Patients With Stage II/III Rectal Cancer", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Rectal Cancer", 
        "condition_browse": {
            "mesh_term": "Rectal Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Patients with histologically confirmed stage II or III rectal cancer (adenocarcinoma)\n\n          2. Patients must be candidates for preoperative chemoradiation\n\n          3. Male or female patients \u226518 years-of-age\n\n          4. Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0 or (see\n             Appendix A)\n\n          5. Adequate hematologic function (within 7 days prior to initial treatment) defined as:\n\n             Absolute neutrophil count (ANC) \u22651500/\u03bcL Platelets \u2265100,000/uL Hemoglobin \u22659 g/dL\n\n          6. Adequate liver function defined as:\n\n             Alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline\n             phosphatase (ALP) \u22643 x the upper limit of normal (UNL) Total bilirubin \u22643.0 mg/dL\n\n          7. Adequate renal function defined as serum creatinine \u22641.6 mg/dL\n\n          8. Male patients willing to use adequate contraceptive measures (see Appendix B)\n\n          9. Female patients who are not of child-bearing potential (see Appendix B), and female\n             patients of child-bearing potential who agree to use adequate contraceptive measures\n             (see Appendix B), who are not breastfeeding, and who have a negative serum or urine\n             pregnancy test <7 days prior\n\n         10. Life expectancy \u226512 weeks\n\n         11. Willingness and ability to comply with the trial and follow-up procedures\n\n         12. Ability to understand the nature of this trial and give written informed consent.\n\n        Exclusion Criteria:\n\n          1. Treatment with prior chemotherapy or radiation for rectal cancer.\n\n          2. Patients who have received any other investigational agents within the 28 days prior\n             to Day 1 of the study.\n\n          3. Known to be human immunodeficiency virus positive or hepatitis B or C positive\n\n          4. Women who are pregnant or breastfeeding\n\n          5. History of acute myocardial infarction within the previous 6 months, uncontrolled\n             hypertension (blood pressure >150/100 mmHg and/or diastolic blood pressure >100\n             mmHg), unstable angina, New York Heart Association Grade 2 or greater congestive\n             heart failure (see Appendix C), serious cardiac arrhythmia requiring medication\n             (excluding atrial fibrillation), or \u2265 Grade 2 peripheral vascular disease.\n\n          6. History of hypertensive crisis or hypertensive encephalopathy.\n\n          7. History of stroke or transient ischemic attack within the past 6 months.\n\n          8. Significant vascular disease (eg, aortic aneurysm requiring surgical repair or recent\n             peripheral arterial thrombosis) within 6 months prior to initiation of therapy.\n\n          9. History of abdominal fistula, gastrointestinal perforation, or intra-abdominal\n             abscess within the past 6 months.\n\n         10. Patients with symptomatic sensory or peripheral neuropathy (Grade 2 or above).\n\n         11. Patients may not have received other agents, either investigational or marketed, that\n             act by primary anti-angiogenic mechanisms.\n\n         12. Prior malignancy (except for adequately treated basal-cell or squamous-cell skin\n             cancers, in situ carcinomas, or low grade [Gleason score of 3+3 or less] localized\n             prostate cancer) in the past 5 years.\n\n         13. Patients with active concurrent infections or patients with serious underlying\n             medical conditions.\n\n         14. Patients receiving full-dose oral or parenteral/SC anticoagulation must be on a\n             stable dosing schedule prior to enrollment; a coumadin dose must be stable for 1\n             week. If this cannot be achieved, the patient will be ineligible for enrollment.\n\n         15. Major surgical procedure or significant traumatic injury within 28 days prior to\n             study initiation, or anticipation of need for major surgical procedure during the\n             course of the study.\n\n         16. Core biopsy or other minor surgical procedure, excluding placement of a vascular\n             access device, within 7 days prior to initiation of therapy.\n\n         17. Patients with external biliary stents.\n\n         18. Patients with proteinuria, as demonstrated by a urine protein of 2+ or greater at\n             screening. If 2+ or greater proteinuria, a 24-hour urine can be obtained, and if the\n             result is <1 gm/24 hours, the patient is eligible.\n\n         19. Any non-healing wound, ulcer, or bone fracture.\n\n         20. Any clinical evidence or history of a bleeding diathesis or significant coagulopathy\n             (in the absence of therapeutic anticoagulation).\n\n         21. History of hemoptysis (\u2265\u00bd teaspoon of bright red blood per episode) within 1 month\n             prior to initiation of therapy.\n\n         22. History of any other disease, physical examination finding, or clinical laboratory\n             finding giving reasonable suspicion of a disease or condition that contraindicates\n             use of an investigational drug or that might affect interpretation of the"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "39", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 12, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01749956", 
            "org_study_id": "SCRI GI 168"
        }, 
        "intervention": [
            {
                "arm_group_label": "FOLFOX6/Aflibercept/Radiation Therapy", 
                "intervention_name": "Radiation Therapy", 
                "intervention_type": "Radiation"
            }, 
            {
                "arm_group_label": "FOLFOX6/Aflibercept/Radiation Therapy", 
                "intervention_name": "Aflibercept", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Eylea", 
                    "Zaltrap"
                ]
            }, 
            {
                "arm_group_label": "FOLFOX6/Aflibercept/Radiation Therapy", 
                "description": "Abdominoperineal or low anterior resection with total mesorectal excision, per standard treatment guidelines", 
                "intervention_name": "Surgery", 
                "intervention_type": "Procedure"
            }, 
            {
                "arm_group_label": "FOLFOX6/Aflibercept/Radiation Therapy", 
                "intervention_name": "FOLFOX6", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Leucovorin (Folinic Acid)", 
                    "5-Fluorouracil (5-FU; Efudex)", 
                    "Oxaliplatin (Eloxatin)"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Fluorouracil", 
                "Oxaliplatin", 
                "Leucovorin"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Rectal Cancer", 
            "Chemoradiation", 
            "Aflibercept", 
            "Surgery"
        ], 
        "lastchanged_date": "April 11, 2014", 
        "location": [
            {
                "contact": {
                    "email": "asksarah@scresearch.net"
                }, 
                "facility": {
                    "address": {
                        "city": "Fort Myers", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33916"
                    }, 
                    "name": "Florida Cancer Specialists"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "AskSARAH@scresearch.net", 
                    "last_name": "AskSARAH"
                }, 
                "facility": {
                    "address": {
                        "city": "Pensacola", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32503"
                    }, 
                    "name": "Woodlands Medical Specialists"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "AskSARAH@scresearch.net", 
                    "last_name": "AskSARAH"
                }, 
                "facility": {
                    "address": {
                        "city": "St. Petersburg", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33705"
                    }, 
                    "name": "Florida Cancer Specialists"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "lindap@spacecoastcancer.com"
                }, 
                "facility": {
                    "address": {
                        "city": "Titusville", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32796"
                    }, 
                    "name": "Space Coast Cancer Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "AskSARAH@scresearch.net", 
                    "last_name": "AskSARAH"
                }, 
                "facility": {
                    "address": {
                        "city": "Louisville", 
                        "country": "United States", 
                        "state": "Kentucky", 
                        "zip": "40207"
                    }, 
                    "name": "Baptist Hospital East"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "AskSARAH@scresearch.net", 
                    "last_name": "AskSARAH"
                }, 
                "facility": {
                    "address": {
                        "city": "Cincinnati", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "45242"
                    }, 
                    "name": "Oncology Hematology Care, Inc."
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Oklahoma City", 
                        "country": "United States", 
                        "state": "Oklahoma", 
                        "zip": "71304"
                    }, 
                    "name": "Oklahoma University"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "AskSARAH@scresearch.net", 
                    "last_name": "AskSARAH"
                }, 
                "facility": {
                    "address": {
                        "city": "Columbia", 
                        "country": "United States", 
                        "state": "South Carolina", 
                        "zip": "29210"
                    }, 
                    "name": "South Carolina Oncology Associates"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "AskSARAH@scresearch.net", 
                    "last_name": "AskSARAH"
                }, 
                "facility": {
                    "address": {
                        "city": "Chattanooga", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37404"
                    }, 
                    "name": "Tennessee Oncology - Chattanooga"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "AskSARAH@scresearch.net", 
                    "last_name": "AskSARAH"
                }, 
                "facility": {
                    "address": {
                        "city": "Nashville", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37203"
                    }, 
                    "name": "Tennessee Oncology, PLLC"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "AskSARAH@scresearch.net", 
                    "last_name": "AskSARAH"
                }, 
                "facility": {
                    "address": {
                        "city": "Richmond", 
                        "country": "United States", 
                        "state": "Virginia", 
                        "zip": "23230"
                    }, 
                    "name": "Virginia Cancer Institute"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase II Study of 5-Fluorouracil (5-FU), Aflibercept, and Radiation for the Preoperative and Adjuvant Treatment of Patients With Stage II/III Rectal Cancer", 
        "overall_contact": {
            "email": "asksarah@scresearch.net", 
            "last_name": "Johanna C Bendell, M.D."
        }, 
        "overall_official": {
            "affiliation": "SCRI Development Innovations, LLC", 
            "last_name": "Johanna C Bendell, M.D.", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Pathologic Complete Response Rate", 
            "safety_issue": "No", 
            "time_frame": "15 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01749956"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "To assess the toxicity of this regimen", 
                "safety_issue": "Yes", 
                "time_frame": "15 months"
            }, 
            {
                "measure": "Evaluate incidence of local and distant recurrence, overall survival (OS) and disease-free survival (DFS)", 
                "safety_issue": "No", 
                "time_frame": "18 months"
            }, 
            {
                "measure": "Evaluate the sphincter preservation rate", 
                "safety_issue": "No", 
                "time_frame": "18 months"
            }, 
            {
                "measure": "Examine the levels of vascular endothelial growth factor A (VEGF-A) and placental growth factor (PLGF) and correlate with response", 
                "safety_issue": "No", 
                "time_frame": "18 months"
            }
        ], 
        "source": "SCRI Development Innovations, LLC", 
        "sponsors": {
            "collaborator": {
                "agency": "Sanofi", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "SCRI Development Innovations, LLC", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}